CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 390 enrolled
Drug / intervention
placebo +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00809471
NCT00809471Phase 3Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Avanafil (TA-1790) in the Treatment of Erectile Dysfunction in Diabetic Men

VIVUS LLC·interventional·Posted Dec 17, 2008·Updated Aug 17, 2012

In Brief

A Phase 3 clinical trial evaluating placebo and avanafil for Erectile Dysfunction. Completed, enrolled 390 participants across 39 sites.

Detailed Summary

This study is being conducted to compare the safety and efficacy of 2 doses of avanafil to placebo in diabetic men with mild to severe erectile dysfunction.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsErectile Dysfunction
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 17, 2008
Enrollment StartDec 1, 2008
Primary CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 17.5 years ago

Interventions

placebodrug

30 minutes orally prior to initiation of sexual activity

avanafildrug

30 minutes orally prior to initiation of sexual activity

avanafildrug

30 minutes orally prior to initiation of sexual activity